Brief: Vivos Therapeutics Announces Additional Strategic Initiatives Aimed At Accelerating Anticipated Timeline For Cash Flow Positive Operations
09/05/2023 14:28
May 9 (Reuters) - Vivos Therapeutics Inc VVOS.O :
* VIVOS THERAPEUTICS ANNOUNCES ADDITIONAL STRATEGIC
INITIATIVES
AIMED AT ACCELERATING ANTICIPATED TIMELINE FOR CASH FLOW
POSITIVE OPERATIONS
* VIVOS THERAPEUTICS INC: APPROXIMATE 17% REDUCTION OF ITS
WORKFORCE
* VIVOS THERAPEUTICS INC - INITIATIVES ARE IN ADDITION TO
COST
SAVING MEASURES PREVIOUSLY ANNOUNCED BY VIVOS
* VIVOS THERAPEUTICS INC: ACCELERATING ITS TARGET TIMES FOR
ACHIEVING POSITIVE CASH FLOW BY A FULL QUARTER
* VIVOS THERAPEUTICS INC: CHANGES ARE EXPECTED TO RESULT IN
RELATIVELY FLAT REVENUES SEQUENTIALLY FOR TRANSITIONAL FIRST
HALF OF 2023
* VIVOS THERAPEUTICS INC: ANTICIPATE TOP LINE REVENUE GROWTH
TO
ACCELERATE BEGINNING IN Q3 OF THIS YEAR
* VIVOS THERAPEUTICS INC: ANTICIPATE REACHING POSITIVE CASH
FLOW
BY Q1 OF 2024
Source text for Eikon: ID:nGNX6JLBls
Further company coverage: VVOS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vivos Therapeutics
See all newsBrief: Vivos Therapeutics Closes Acquisition Of Stake In Sod Sciences And 50% Interest In Pseudohypoxia Test, Opening A Potential Path To Access More Than 325,000 New Patients Through The Aha Channel
Brief: Vivos Therapeutics - Audit Reports For Fy2025 And Fy2024 Include Substantial Doubt About Going Concern
Brief: Vivos Therapeutics And South Palm Cardiovascular Associates Sign Definitive Agreements To Launch Regional Sleep Testing And Treatment Center
Vivos Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Vivos Therapeutics Q2 revenue rises 35% on service growth